Abstract: Antibodies and antigen-binding fragments thereof that bind type II transmembrane serine protease 6 (TMPRSS6) on the surface of a cell and increase hepcidin expression, and methods for treating disorders of iron metabolism and myeloproliferative disorders using anti-TMPRSS6 antibodies and fragments, are provided.

Abstract: Antibodies and antigen-binding fragments thereof that bind type II transmembrane serine protease 6 (TMPRSS6) on the surface of a cell and increase hepcidin expression, and methods for treating disorders of iron metabolism using anti TMPRSS6 antibodies and fragments, are provided.

Abstract: Provided herein are antibodies that specifically bind to MICA/B having heavy chain, light chain, variable heavy chain domains (VH), variable light chain domains (VL), and complementarity determining regions (CDRs) disclosed herein, as well as methods and uses thereof.

Abstract: An oral preparation containing a progestogen, and a preparation method and the use. The oral preparation does not contain or contains only benzyl benzoate in a weight percentage of less than 8%. The preparation contains 17-? hydroxyprogesterone caproate, propylene glycol monocaprylate, PEG35 castor oil, and propylene glycol monolaurate. The oral preparation provides good stability, dissolution performance, and bioavailability while ensuring high safety.

Abstract: The present disclosure provides anti-amyloid ? (A?) antibodies and antibody fragments that preferentially bind soluble amyloid A? protofibril/oligomer and trigger ADPC in microglial cells, anti-amyloid ? (A?) antibodies and antibody fragments that reduce soluble amyloid A? protofibril/oligomer levels and insoluble amyloid A? plaque in brain tissue, and the use of anti-A? protofibril/oligomer antibodies and antibody fragments in therapy, prophylaxis, diagnosis, screening, and monitoring of conditions associated with A? protein aggregation, in particular Alzheimer's disease (AD).

Abstract: A treatment method for interstitial pneumonia by means of hydroxyprogesterone caproate alone or in combination with other drugs, and corresponding pharmaceutical uses, and pharmaceutical compositions. Hydroxyprogesterone caproate can reduce pulmonary inflammation and fibrosis symptoms, reduce pulmonary collagen deposition, and reduce the levels of various inflammatory factors in bronchoalveolar lavage fluid and plasma. Hydroxyprogesterone caproate combined with dexamethasone can improve lipid metabolism abnormalities caused by dexamethasone treatment alone.

Abstract: The present disclosure provides anti-amyloid ? (A?) antibodies and antibody fragments that preferentially bind soluble amyloid A? protofibril/oligomer and trigger ADPC in microglial cells, anti-amyloid ? (A?) antibodies and antibody fragments that reduce soluble amyloid A? protofibril/oligomer levels and insoluble amyloid A? plaque in brain tissue, and the use of anti-A? protofibril/oligomer antibodies and antibody fragments in therapy, prophylaxis, diagnosis, screening, and monitoring of conditions associated with A? protein aggregation, in particular Alzheimer's disease (AD).

Abstract: Disclosed herein, in certain embodiments, are compositions, solutions, and soft gelatin capsules comprising 17-alpha hydroxyprogesterone caproate (17-HPC). In certain embodiments, also disclosed herein are methods, dosing regimens, and kits for use in the treatment of a disease or condition.

Abstract: Provided herein are antibodies that specifically bind to MICA/B having heavy chain, light chain, variable heavy chain domains (VH), variable light chain domains (VL), and complementarity determining regions (CDRs) disclosed herein, as well as methods and uses thereof.

Abstract: The present disclosure provides anti-amyloid ? (A?) antibodies and antibody fragments that preferentially bind soluble amyloid A? protofibril/oligomer and trigger ADPC in microglial cells, anti-amyloid ? (A?) antibodies and antibody fragments that reduce soluble amyloid A? protofibril/oligomer levels and insoluble amyloid A? plaque in brain tissue, and the use of anti-A? protofibril/oligomer antibodies and antibody fragments in therapy, prophylaxis, diagnosis, screening, and monitoring of conditions associated with A? protein aggregation, in particular Alzheimer's disease (AD).

Abstract: Antibodies and antigen-binding fragments thereof that bind C1s and inhibit C1s activity and modulate the activity of at least one component in the classical pathway (CP) of complement activation, and methods for treating complement-mediated disorders using anti-C1s antibodies and fragments, are provided.

Abstract: Antibodies and antigen-binding fragments thereof that bind C1s and inhibit C1s activity and modulate the activity of at least one component in the classical pathway (CP) of complement activation, and methods for treating complement-mediated disorders using anti-C1s antibodies and fragments, are provided.

Abstract: Provided herein are antibodies that specifically bind to MICA/B having variable heavy chain domains (VH), variable light chain domains (VL), and complementarity determining regions disclosed herein, as well as methods and uses thereof.

Abstract: This application provides the use of zanamivir in the preparation of drugs for the treatment or prevention of pre-eclampsia and the corresponding drugs and therapeutic methods; Zanamivir is effective in improving the symptoms of hypertension, proteinuria, elevated creatinine, neuraminidase and sialic acid in pre-eclampsia, increasing NO levels; and improving pregnancy outcomes. The combination of zanamivir and hydroxyprogesterone caproate showed superior results.

Abstract: Antibodies and antigen-binding fragments thereof that bind type II transmembrane serine protease 6 (TMPRSS6) on the surface of a cell and increase hepcidin expression, and methods for treating disorders of iron metabolism using anti TMPRSS6 antibodies and fragments, are provided.

Abstract: Antibodies and antigen-binding fragments thereof that bind type II transmembrane serine protease 6 (TMPRSS6) on the surface of a cell and increase hepcidin expression, and methods for treating disorders of iron metabolism using anti TMPRSS6 antibodies and fragments, are provided.

Abstract: A method of killing insects on or around an intact plant, comprising the step of depositing or suspending in the air a composition comprising synthetic amorphous silica (SAS) on or around the intact plant.

Abstract: A method of killing insects on or around stored products or in structures, comprising the step of depositing or suspending in the air a composition comprising a mixture of hydrophilic synthetic amorphous silica (SAS) and hydrophobic SAS on or around the stored products or structure.

Abstract: Antibodies and antigen-binding fragments thereof that bind type II transmembrane serine protease 6 (TMPRSS6) on the surface of a cell and increase hepcidin expression, and methods for treating disorders of iron metabolism and myeloproliferative disorders using anti TMPRSS6 antibodies and fragments, are provided.

Abstract: Antibodies and antigen-binding fragments thereof that bind type II transmembrane serine protease 6 (TMPRSS6) on the surface of a cell and increase hepcidin expression, and methods for treating disorders of iron metabolism using anti TMPRSS6 antibodies and fragments, are provided.